HK1247816A1 - 普那布林联合免疫检查点抑制剂的用途 - Google Patents

普那布林联合免疫检查点抑制剂的用途 Download PDF

Info

Publication number
HK1247816A1
HK1247816A1 HK18107194.9A HK18107194A HK1247816A1 HK 1247816 A1 HK1247816 A1 HK 1247816A1 HK 18107194 A HK18107194 A HK 18107194A HK 1247816 A1 HK1247816 A1 HK 1247816A1
Authority
HK
Hong Kong
Prior art keywords
alpha
immune checkpoint
cancer
checkpoint inhibitor
inhibitor
Prior art date
Application number
HK18107194.9A
Other languages
English (en)
Chinese (zh)
Inventor
黄岚
黃嵐
李自宜
Original Assignee
大连万春布林医药有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大连万春布林医药有限公司 filed Critical 大连万春布林医药有限公司
Publication of HK1247816A1 publication Critical patent/HK1247816A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK18107194.9A 2015-02-12 2016-02-11 普那布林联合免疫检查点抑制剂的用途 HK1247816A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562115468P 2015-02-12 2015-02-12
US62/115,468 2015-02-12
US201562255259P 2015-11-13 2015-11-13
US62/255,259 2015-11-13
PCT/US2016/017602 WO2016130839A1 (en) 2015-02-12 2016-02-11 Use of plinabulin in combination with immune checkpoint inhibitors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
HK42024088264.7A Division HK40099485A (zh) 2015-02-12 2018-05-31 普那布林联合免疫检查点抑制剂的用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
HK42024088264.7A Addition HK40099485A (zh) 2015-02-12 2018-05-31 普那布林联合免疫检查点抑制剂的用途

Publications (1)

Publication Number Publication Date
HK1247816A1 true HK1247816A1 (zh) 2018-10-05

Family

ID=56615698

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18107194.9A HK1247816A1 (zh) 2015-02-12 2016-02-11 普那布林联合免疫检查点抑制剂的用途

Country Status (16)

Country Link
US (1) US20180028531A1 (enExample)
EP (1) EP3256130A4 (enExample)
JP (4) JP7243021B2 (enExample)
KR (2) KR20170117113A (enExample)
CN (2) CN107427510A (enExample)
AU (3) AU2016219204B2 (enExample)
CA (1) CA2975729A1 (enExample)
CL (1) CL2017002050A1 (enExample)
HK (1) HK1247816A1 (enExample)
IL (2) IL286282B2 (enExample)
MX (2) MX394865B (enExample)
MY (1) MY193968A (enExample)
NZ (1) NZ734256A (enExample)
RU (1) RU2723021C2 (enExample)
SG (1) SG11201706281YA (enExample)
WO (1) WO2016130839A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101495951B1 (ko) 2009-03-30 2015-02-25 에자이 알앤드디 매니지먼트 가부시키가이샤 리포솜 조성물
CA2974651A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
RU2728796C2 (ru) 2015-03-06 2020-07-31 Бейондспринг Фармасьютикалс, Инк. Способ лечения опухоли головного мозга
SG10202008673WA (en) 2015-03-06 2020-10-29 Beyondspring Pharmaceuticals Inc Method of treating cancer associated with a ras mutation
HK1252026A1 (zh) * 2015-06-11 2019-05-10 Bionomics Limited 药物组合及其应用
CN109516981B (zh) 2015-07-13 2019-10-22 大连万春布林医药有限公司 普那布林组合物
US10912748B2 (en) 2016-02-08 2021-02-09 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
EP3449921B1 (en) 2016-04-28 2023-05-31 Eisai R&D Management Co., Ltd. Eribulin for inhibiting tumor growth
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
KR20240091084A (ko) 2016-06-06 2024-06-21 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증을 줄이는 조성물 및 방법
CN109906088A (zh) 2016-08-26 2019-06-18 奥野哲治 微血管血流减少剂及其应用
WO2018071792A1 (en) * 2016-10-14 2018-04-19 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
JP2020503363A (ja) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合化合物およびその治療的使用
IL268305B2 (en) 2017-02-01 2024-08-01 Beyondspring Pharmaceuticals Inc Plinabulin in combination with one or more g-csf drug for use in the therapeutic treatment of docetaxel-induced
BR112019018880A2 (pt) * 2017-03-13 2020-04-14 Beyondspring Pharmaceuticals Inc composições de plinabulina e seu uso
WO2019022501A1 (en) * 2017-07-26 2019-01-31 Chong Kun Dang Pharmaceutical Corp. COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER COMPRISING A VASCULAR DISRUPTION AGENT AND AN IMMUNE CONTROL POINT INHIBITOR
CA3074876A1 (en) * 2017-09-08 2019-03-14 University Health Network Combination therapies for inhibition of polo-like kinase 4
CN109498627B (zh) * 2017-09-15 2021-06-04 深圳华大海洋科技有限公司 一种治疗肿瘤的药物组合物及其应用
US11786523B2 (en) 2018-01-24 2023-10-17 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia
JP7500438B2 (ja) * 2018-06-01 2024-06-17 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド Ｅｇｆｒ変異に関連する癌の治療組成物及び治療方法
CN108524442B (zh) * 2018-06-05 2022-01-28 深圳海王医药科技研究院有限公司 一种抗肿瘤药物的注射剂及其制备方法
US20210177952A1 (en) * 2018-08-16 2021-06-17 Beyondspring Pharmaceuticals, Inc. Method and composition for stimulating immune response
US20210369787A1 (en) * 2018-11-01 2021-12-02 North Carolina State University Adipocyte mediated delivery of anticancer therapeutics
CN110265095A (zh) * 2019-05-22 2019-09-20 首都医科大学附属北京佑安医院 用于hcc复发及rfs的预测模型和诺模图的构建方法及应用
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
CN112778155B (zh) * 2019-11-11 2023-08-11 大连万春布林医药有限公司 妥卡雷琐衍生物及其用途
US20230181605A1 (en) * 2020-05-04 2023-06-15 Beyondspring Pharmaceuticals, Inc. Triple combination therapy for enhancing cancer cell killing in cancers with low immunogenicity
WO2022133492A1 (en) * 2020-12-18 2022-06-23 Beyondspring Pharmaceuticals, Inc. Compositions and methods for generating anti-tumor immune response
JP2024513505A (ja) 2021-04-09 2024-03-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 腫瘍を治療するための組成物及び方法
CN113456643B (zh) * 2021-08-11 2022-04-01 遵义医科大学 一种含普那布林的药物组合及其应用
CN117860672A (zh) 2022-10-11 2024-04-12 大连万春布林医药有限公司 一种普那布林胶束组合物及其制备方法
CN121127241A (zh) * 2023-03-10 2025-12-12 万春药业公司 肿瘤联合治疗及使用方法
WO2025006507A1 (en) * 2023-06-27 2025-01-02 Beyondspring Pharmaceuticals, Inc. Oncology combination therapy and methods of use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05001217A (es) * 2002-08-02 2005-05-16 Nereus Pharmaceuticals Inc Deshidrofenilahistinas y sus analogos y la sintesis de deshidrofenilahistinas y sus analogos.
CA2553630A1 (en) * 2004-02-04 2005-08-25 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
CN109485727A (zh) * 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
US8569262B2 (en) * 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
EP2227296B1 (en) * 2008-01-08 2015-11-25 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with tubulin modulating agents for the treatment of proliferative diseases
CN102256944A (zh) * 2008-10-17 2011-11-23 埃克塞利希斯股份有限公司 鞘氨醇-1-磷酸受体拮抗剂
JP5855568B2 (ja) * 2009-09-15 2016-02-09 セルリアン・ファーマ・インコーポレイテッド 癌の治療法
WO2011146382A1 (en) * 2010-05-17 2011-11-24 Bristol-Myers Squibb Company Improved immunotherapeutic dosing regimens and combinations thereof
WO2012035436A1 (en) * 2010-09-15 2012-03-22 Tokyo University Of Pharmacy And Life Sciences Plinabulin prodrug analogs and therapeutic uses thereof
WO2013090552A1 (en) * 2011-12-13 2013-06-20 Yale University Compositions and methods for reducing ctl exhaustion
AU2013308595C1 (en) * 2012-08-30 2019-01-17 Amgen Inc. A method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor
WO2014066834A1 (en) * 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
SG11201505896YA (en) * 2013-02-20 2015-09-29 Novartis Ag Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
US11083743B2 (en) * 2013-02-21 2021-08-10 Michele Maio DNA hypomethylating agents for cancer therapy
US10260038B2 (en) * 2013-05-10 2019-04-16 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
KR20160013049A (ko) * 2013-06-03 2016-02-03 노파르티스 아게 항-pd-l1 항체 및 mek 억제제 및/또는 braf 억제제의 조합물
WO2015051543A1 (en) * 2013-10-11 2015-04-16 Dalian Wanchun Biotechnology Co., Ltd. Cancer treatment with combination of plinabulin and taxane
US10912748B2 (en) * 2016-02-08 2021-02-09 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs

Also Published As

Publication number Publication date
RU2017127966A3 (enExample) 2019-06-20
CL2017002050A1 (es) 2018-04-13
IL286282B2 (en) 2023-10-01
CN117100753A (zh) 2023-11-24
AU2016219204A1 (en) 2017-08-24
NZ750444A (en) 2021-03-26
MX2017010338A (es) 2017-12-20
CA2975729A1 (en) 2016-08-18
BR112017016902A2 (pt) 2018-03-27
AU2016219204B2 (en) 2021-01-21
EP3256130A4 (en) 2018-08-01
AU2021202416B2 (en) 2024-02-15
JP2022190005A (ja) 2022-12-22
IL286282B1 (en) 2023-06-01
RU2017127966A (ru) 2019-03-12
SG11201706281YA (en) 2017-09-28
WO2016130839A1 (en) 2016-08-18
MX394865B (es) 2025-03-24
NZ734256A (en) 2019-02-22
AU2021202416A1 (en) 2021-05-20
RU2723021C2 (ru) 2020-06-08
JP2024174070A (ja) 2024-12-13
MY193968A (en) 2022-11-03
JP7157181B2 (ja) 2022-10-19
CN107427510A (zh) 2017-12-01
MX2022007472A (es) 2022-06-29
IL253784A0 (en) 2017-09-28
JP7564172B2 (ja) 2024-10-08
KR20240110996A (ko) 2024-07-16
IL253784B (en) 2021-09-30
JP7243021B2 (ja) 2023-03-22
JP2018508572A (ja) 2018-03-29
AU2024200672A1 (en) 2024-02-22
KR20170117113A (ko) 2017-10-20
US20180028531A1 (en) 2018-02-01
JP2021050247A (ja) 2021-04-01
EP3256130A1 (en) 2017-12-20
IL286282A (en) 2021-10-31

Similar Documents

Publication Publication Date Title
JP7564172B2 (ja) 免疫チェックポイント阻害薬と併用するプリナブリンの使用
US11857522B2 (en) Compositions containing tucaresol or its analogs
US20230181605A1 (en) Triple combination therapy for enhancing cancer cell killing in cancers with low immunogenicity
US12377094B2 (en) Therapeutic compositions and methods for treating checkpoint inhibitor-resistant tumors using plinabulin-based combination therapies
US20250073230A1 (en) Use of plinabulin in combination with immune checkpoint inhibitors
CA3147071A1 (en) Methods of treatment
NZ750444B2 (en) Use of plinabulin in combination with immune checkpoint inhibitors
BR112017016902B1 (pt) Composição farmacêutica, respectivo uso e uso de plinabulina
TW202315631A (zh) 增強低免疫原性癌症中癌細胞毒殺的三聯療法
CN117615761A (zh) 用于治疗肿瘤的治疗组合物和方法